Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Conference call to be held Monday ...

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival. Relay Therapeutics, Inc. Mon, Sep 9, 2024, 6:55 AM 11 min read.

Potential Positives. Updated interim clinical data for RLY-2608 show a median progression free survival (PFS) of 11.0 months in second line (2L) patients with PI3Kα-mutated, HR+, HER2- metastatic ...

O RLANDO, Fla. — Researchers presented early-phase trial results on RLY-2608, Relay Therapeutics’ next-generation PI3K inhibitor, at the American Association for Cancer Research annual meeting ...